Santaris Study Shows HCV Drug Inhibits miRNA Target in Chimps | GenomeWeb

By Doug Macron

Researchers from Santaris Pharma this week published data in Science showing that intravenous administration of its phase I hepatitis C therapy SPC3649 could silence its target microRNA in chimpanzees infected with the virus without triggering resistance or adverse effects.

Separately, an official from Santaris confirmed that GlaxoSmithKline's option to license the drug has expired, and that deal negotiations are underway with other companies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.